The report forecasts Divi's Labs EBITDA growth of 32.6% YoY in 2QFY27.
Read this note →Research notes
What India's research desks published, reported with attribution and linked to the original notes. Orivam issues no recommendations of its own.
All houses
HDFC Securities
Motilal Oswal
Tata Asset Management
Mirae Asset Sharekhan
Jainam
India IPO
GEPL Capital
Way2Wealth
SBICAP Securities
Angel One
Axis Securities
ICICI Direct Research Retail
Formerly known as Way2Wealth
Religare
Arete Securities
ICICI Direct
Way2Wealth Securities
ICICI Securities
quant Mutual Fund
Kotak Securities
JM Financial
ICICI Securities – Retail
Ventura Securities
Global Markets by Vested
Prabhudas Lilladher
ITC Hotels
Elara Securities
Exterminators PLC
Emkay Global
Industrial Asphalts
Private Client Group Research summarized from KIE research report
Kahawatte Plantations PLC
2581 notes · all time
The report expects Dr Agarwal's sales to grow 24.3% YoY and PAT to grow 36.3% YoY in 2QFY27.
Read this note →The report states Cipla's US sales are expected to decline 27% YoY to USD162m due to g-Revlimid competition, dragging EBITDA down 30% YoY.
Read this note →The report forecasts Biocon sales growth of 4.1% YoY but PAT growth of 54.1% YoY in 2QFY27.
Read this note →The report notes Aurobindo underwent two USFDA inspections in September 2026 resulting in Form 483 observations, and forecasts sales growth of 16.1% YoY.
Read this note →The report expects Aster to deliver 1.2x/1.2x/1.6x YoY growth in sales/EBITDA/PAT owing to the merger with QCIL, and plans to add 634 beds in FY27.
Read this note →The report expects Apollo to post 19%/20%/26% YoY growth in sales/EBITDA/PAT in 2QFY27 and is set to operationalize ~620 beds across metro markets.
Read this note →The report forecasts Alkem sales growth of 9.5% YoY and EBITDA growth of 8.4% YoY with PAT declining 13.0% YoY in 2QFY27.
Read this note →The report notes Alembic is expected to underperform peers with DF sales growth of 6.8% YoY owing to muted performance in acute and chronic segments, though it also expects 55% YoY US growth supported by Bosutinib exclusivity.
Read this note →The report expects Ajanta's sales to grow 18.5% YoY driven by US and Africa segments, with DF growth of 15% YoY.
Read this note →The note says Sindhuja Microcredit raised ₹100 crore through non-convertible debentures with AUM of ₹1,059 crore.
Read this note →The note says Bajaj Auto recorded a decline in September two-wheeler sales.
Read this note →The note says Royal Enfield posted growth in September two-wheeler sales.
Read this note →The note says TVS Motor posted growth in September two-wheeler sales.
Read this note →The note says Hero MotoCorp posted growth in September two-wheeler sales.
Read this note →The note lists Hyundai among those leading September passenger vehicle sales growth.
Read this note →The note lists Mahindra among those leading September passenger vehicle sales growth.
Read this note →The note lists Tata Motors among those leading September passenger vehicle sales growth.
Read this note →The note says Maruti Suzuki was among the carmakers leading a 21.4% year-on-year rise in September passenger vehicle sales.
Read this note →The note says Wipro is expected to face modest growth in Q2 FY27.
Read this note →The note says TCS is expected to face modest growth in Q2 FY27.
Read this note →The note says Infosys is expected to face modest growth in Q2 FY27.
Read this note →The note says HCLTech is expected to lead growth among large-cap Indian IT firms in Q2 FY27.
Read this note →The note says Accenture raised FY27 revenue-growth guidance to 3–6% after Q4 revenue and bookings beat estimates.
Read this note →The note says Adani Green Energy expanded operational battery storage capacity to 6.63 GWh while pursuing 50 GWh capacity and pumped-storage projects.
Read this note →